ABBV has outperformed expectations, with Humira remaining the market leader with 98% share despite the LOE and biosimilar headwinds.Combined with Elahere's recent US FDA approval with a projected TAM ...
Source LinkABBV has outperformed expectations, with Humira remaining the market leader with 98% share despite the LOE and biosimilar headwinds.Combined with Elahere's recent US FDA approval with a projected TAM ...
Source Link
Comments